Explore a continuación la lista completa de nuestras notas de prensa (página 6 de 28):
Egypt is certified malaria-free by WHO, becoming the third country in its region to achieve this milestone.
Eleven monkeys died from melioidosis infection at Hong Kong Zoo, likely due to contaminated soil brought into enclosures.
VYLOY is the first CLDN18.2-targeted therapy that has gained FDA approval for treating advanced gastric and GEJ cancer.
The investigational once-weekly islatravir and lenacapavir combination shows 94.2% viral suppression in HIV patients after 48 weeks.
Angelini Pharma partners with Cureverse to advance CV-01, a breakthrough brain health treatment, securing global development rights.
CHMP recommends WAINZUA (eplontersen) for EU approval to treat hereditary polyneuropathy, offering a potential self-administered option.
Paris backs a €15 billion sale of Sanofi's paracetamol unit to US fund CD&R, ensuring job security and no impact on essential medicines.
MIRA's KETAMIR-2 shows superior efficacy and safety over current therapies in preclinical pain management studies.
Novo Nordisk’s concizumab receives FDA fast-track status, accelerating development for hemophilia A and B treatment.
Amneal's NDA for Pyridostigmine Bromide Extended-Release tablets gets FDA approval for nerve agent poisoning treatment in military use.
Inventiva to present Phase 2 LEGEND study on lanifibranor & empagliflozin in MASH & T2D at AASLD Liver Meeting 2024, Nov 18, 8 AM-5 PM PST, San Diego.
Acurx announces evaluation of the new Phase 2B trial of Ibezapolstat, presented at the IDWeek meeting.
Recursion partners with Google Cloud to leverage AI and tech for faster, cost-effective drug discovery.
Nucleus expands R&D and manufacturing capacity to address radiopharmaceutical supply chain constraints with two new sites.
Pharma Tech Industries names Darrin Schellin as CEO to drive innovation and growth in contract manufacturing.
ABIONYX Pharma advances CER-001 for LCAT deficiency with EMA support, completing a key step in its EU conditional approval process.
B.Grimm Pharma partners with Inter Mohosot to expand access to essential medicines in Cambodia, improving healthcare for key conditions.
WHO and SNOMED International discuss linking ICD-11 and SNOMED CT to improve global health data interoperability.
Recursion's Phase 2 trial begins with the first patient dosed, testing REC-994 for cerebral cavernous malformation (CCM).
Scorpius Holdings forms a strategic partnership with U.S. biotech, transferring RCB for future biomanufacturing.
Alvotech and Teva's SELARSDI receives FDA approval for a new formulation, launching in the U.S. by early 2025.
Aligos receives FDA approval for Phase 1 study of ALG-000184, targeting Chronic Hepatitis B with potential superior efficacy.
Peli BioThermal introduces the Credo Vault, ensuring safe transport of temperature-sensitive pharmaceuticals globally.
Lonza opens a new facility in Geleen, Netherlands, to boost production of plasmid DNA for gene therapies.
Indaptus and BeiGene will start a 2025 trial combining Decoy20 with PD-1 inhibitor tislelizumab for innovative cancer treatment.
Samsung Biologics inks a $1.24B deal with an Asia pharma giant, expanding global manufacturing through 2037.
Parexel appoints Keri Mattox as Chief Business Officer to drive growth and innovation in a pivotal leadership shift.
Bormioli Pharma and Chiesi launch Carbon Capture PET bottles, reducing CO2 emissions by 21.9% in pharma packaging.
NorthStar Medical Opens A New Facility In Beloit, boosting radiopharmaceutical production for cancer therapies & medical imaging.
Avantor strengthens its partnership with NIBRT, enhancing biopharma manufacturing and training critical industry talent.
Cold Chain Technologies strengthens its product portfolio and global presence by acquiring Tower Cold Chain’s reusable packaging.
Kane Biotech donates revyve™ Antimicrobial Wound Gel to Ukraine, aiding the treatment of war-related injuries.
Agios finishes Phase 3 trial enrolment for Mitapivat, aiming to improve treatment of sickle cell disease.
Alphina Therapeutics names Nick Galli as CEO to lead the development of its promising NAMPT inhibitor for solid tumors.
Schreiner MediPharm and WuXi XDC create an innovative Light-Protect-Label for ADCs, ensuring drug safety in trials.
SwRI's new 21,000-square-foot facility will enhance its R&D for small-batch therapeutics, vaccines, and stem cell therapies.
United Therapeutics and Lung Bioengineering celebrate 500 EVLP lung transplants, advancing transplant access with innovative organ evaluation technologies.
NImmune Biopharma gains exclusive rights to develop and commercialize omilancor for I&I conditions in Asia, advancing Phase 3 trials for ulcerative colitis.
Evotec and Bristol Myers Squibb expand their partnership with a $50M investment to advance drug discovery using molecular glue technologies.
Merck acquires Modifi Biosciences for $30M, aiming to boost cancer therapies targeting DNA repair-deficient tumors, with up to $1.3B in milestones.
Merck’s CAPVAXIVE™ earns CDC ACIP recommendation for pneumococcal vaccination in adults 50+, enhancing protection against pneumonia.
Merck's Keytruda secures its 30th European approval, expanding into treatments for gynecologic cancers.
Rigel Pharmaceuticals issues safety advisory for GAVRETO to providers, stressing vigilance in cancer patient care.
Rhythm Pharmaceuticals partners with Axovia Therapeutics for research to better understand Bardet-Biedl syndrome.
AbbVie partners with Richter to discover and develop neuropsychiatric treatments, building on years of CNS research.
ImmunityBio begins trial in South Africa testing CD19 CAR-NK cell therapy for relapsed non-Hodgkin’s lymphoma.
Matica Biotechnology and KaliVir Immunotherapeutics team up to advance scalable viral vector production for cancer therapies.
Walgreens and Veeva Unite to transform pharma collaboration and enhance patient outcomes through integrated data solutions.
Coronado Research appoints Professor Jennifer Visser-Rogers as Chief Scientific Officer to advance clinical research.
Inozyme Pharma shares promising Phase 1 trial results for INZ-701 in ESKD patients at ASN Kidney Week 2024.
Rentschler Biopharma announces a record investment for a new buffer media station in Laupheim, enhancing production efficiency.
Fabhalta by Novartis demonstrates significant one-year benefits for C3G, showing sustained proteinuria reduction and improved kidney function.
Phathom Pharmaceuticals will present VOQUEZNA findings at the ACG meeting, exploring the efficacy of as-needed treatment for GERD relief.
Astellas pulls EMA application for ACP but remains committed to advancing GA treatment options across Europe.
AstraZeneca's Fasenra (benralizumab) receives EU approval for eosinophilic granulomatosis with polyangiitis, providing new hope for patients.
Recce Pharmaceuticals advances its Phase II ABSSSI trial for R327G, showing promising results for diabetic foot infections.
Lilly’s mirikizumab demonstrates sustained remission in UC and Crohn’s patients, with strong safety and symptom control.
Shuttle Pharma launches Phase 2 trial of Ropidoxuridine, aiming to enhance radiation treatment for glioblastoma patients.
Merck and Moderna launched Phase 3 of the V940 trial with KEYTRUDA, targeting non-small cell lung cancer patients post-surgery.
MIRA’s Ketamir-2 significantly outperforms gabapentin in preclinical chemotherapy-related neuropathic pain relief trials.
Monte Rosa licenses MRT-6160 and VAV1-targeting MGDs to Novartis for global development in immune-mediated diseases.
Chime Biologics partners with MedPacto to enhance biomanufacturing capabilities and advanced cancer therapeutics in South Korea.
Sai Life Sciences achieves FDA approval for Indian sites, reinforcing quality and compliance in global CRDMO operations.
Evoke Pharma, in partnership with EVERSANA, reveals GIMOTI's effectiveness in reducing healthcare visits for DGP patients.
AbbVie will acquire Aliada Therapeutics for $1.4 billion, focusing on innovative therapies for CNS diseases like Alzheimer’s.
CluePoints names Richard Young as Chief Strategy Officer to boost innovation in Risk-Based Quality Management.
First volunteers receive a long-acting injectable in a pivotal trial aimed at enhancing malaria prevention and combating this deadly disease.
Ryvu and nCage unite to create ADCs using TRAP cage tech, enhancing targeted cancer therapy safety and efficacy.
Naobios and Sumagen achieve a key production milestone for the SAV001 HIV-1 vaccine, moving closer to clinical trials.
Ardena announces a new bioanalytical lab in Oss and expands Assen's capabilities to support diverse drug development needs.
Merck invests €70M in St. Louis facility to triple ADC capacity, advancing targeted cancer and bioconjugate treatments.
In October 2024, WHO's Global Health Emergency Corps activates to aid 18 African nations in fighting mpox outbreaks.
Genascence appoints Dr. Jeymi Tambiah as the CMO, who brings extensive experience in gene therapy and clinical development leadership.
Shuttle Pharma's Phase 2 trial doses initial glioblastoma patients with Ropidoxuridine to boost radiation therapy outcomes.
Antheia achieves milestone with first commercial thebaine delivery, advancing resilient biomanufacturing for essential medicine production.
Resolian announces leadership changes, with Rob Stachlewitz as CEO, aiming to enhance global growth and innovation.
PharmaLogic opens a new radiopharmaceutical facility in Los Angeles, enhancing production and research to improve patient care and diagnostics.
Kiora Pharmaceuticals prepares Phase 2 trial of KIO-301 to explore vision restoration in patients with retinitis pigmentosa.
Celltrion debuts Steqeyma, its Stelara biosimilar, in Germany, planning broader EU expansion to boost market presence.
Volpara Health signs a $7.3M DHA contract to supply breast cancer screening software across U.S. military facilities.
CinFina Pharma’s CIN-109 and CIN-110 demonstrate strong Phase 1 results for weight reduction and appetite control.
Lokon Pharma and BeiGene team up in a Phase 2 trial to target pancreatic cancer with a new gene therapy combo.
Cytoki Pharma has begun Phase 2 trials for CK-0045, targeting obesity and type 2 diabetes, with results anticipated in 2026.
Tonix Pharmaceuticals teams with KEMRI to develop TNX-801 vaccine for mpox and smallpox, aiming for effective global response.
Alvotech & Advanz Pharma seek EMA approval for AVT05, a Simponi® biosimilar, promising cost-effective inflammatory care.
NeuroBo Pharmaceuticals finishes dosing in its Phase 2a study of DA‑1241 for Metabolic dysfunction‑associated steatohepatitis (MASH), an important step toward topline data expected in December 2024.
Scorpius partners with Celltheon to provide advanced cell line development, biomanufacturing services and scaling to GMP.
Alan Bash is appointed as the President of CARVYKTI® at Legend Biotech, leading commercial, technical, & quality operations.
Ascendis collaborates with Novo Nordisk and grants exclusive rights to TransCon tech for metabolic and cardiovascular drugs.
Conduit Pharmaceuticals secures patents for CDT1656, combining AZD1656 with a novel compound to target autoimmune disorders.
Syndax Pharmaceuticals has partnered with Royalty Pharma in a $350M synthetic royalty agreement for Niktimvo sales.
Catalyx and INEL unite to enhance pharmaceutical packaging with innovative automation, improving efficiency, compliance, and inspection processes globally.
CureVac N.V. appoints Axel Sven Malkomes as CFO, bringing 30 years of biotech finance experience to drive growth in mRNA therapies.
Synaffix collaborates with BigHat to advance ADC development, leveraging AI for antibody design and effective targeting.
Olon's Rodano facility for ultra-potent compounds will be operational by January 2025, ensuring safer API handling.
FUJIFILM Diosynth and TG Therapeutics partner for multi-year BRIUMVI® manufacturing, beginning operations in 2025.
Evotec SE divests Halle site to Monacum Partners, supporting core focus and growth strategy through "Priority Reset."
Acadia Pharmaceuticals sells Rare Pediatric Disease PRV for $150M, with proceeds supporting CNS and rare disease R&D. Neuren to receive one-third share.
Tarsus names Dr. Elizabeth Yeu as Chief Medical Officer, strengthening its commitment to advancing eye care innovation and patient outcomes.
FUJIFILM Diosynth starts global expansion, increasing production and creating 2,200 jobs to meet healthcare demands.
Legend Biotech's CARTITUDE-4 data at ASH 2024 shows CARVYKTI®'s superior MRD negativity in multiple myeloma patients.
iotaSciences launches advanced XT platform for automated single-cell cloning, aiding cell line development and gene editing.
WHO identifies 17 critical pathogens for new vaccine development, targeting major health burdens and antimicrobial threats.
Hanmi’s HM17321 obesity treatment targets fat reduction while preserving muscle, presenting a novel approach to metabolic health.
Pharos iBio’s PHI-101 demonstrates 50% complete response in AML phase 1 trial, targeting FLT3 mutation for potential early commercialization.
Dupixent® (dupilumab) is now approved in the EU for treating eosinophilic esophagitis (EoE) in children as young as one, offering a new treatment option.
The Access and Allocation Mechanism distributes 900,000 mpox vaccines to African countries, prioritizing highest-need regions.
Plus Therapeutics partners with SpectronRx to produce Rhenium (186Re) Obisbemeda for CNS cancer treatment.
Redwire, in collaboration with Eli Lilly, returns ISS-grown insulin crystals with potential to accelerate drug discovery.
I-Mab appoints Dr. Sean Fu as permanent CEO, bringing decades of life sciences and biotech expertise.
Acumen Pharmaceuticals announces the appointment of Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality to advance Alzheimer's therapies.
Cumberland's Ifetroban receives Orphan Drug and Rare Pediatric Disease designations for DMD-related cardiomyopathy treatment.
Kwality Pharma gains EU entry as Greece approves Leuprorelin, expecting $3M yearly sales from strategic CDMO deal.
Biosynth names Matt Gunnison CEO and Kieran Murphy Chairman to drive growth and innovation in life sciences.
Sonrai Analytics partners with MGH’s Termeer Center to integrate AI tech for faster, more efficient analysis of complex cancer research data.
Xilio’s vilastobart shows encouraging early data in treating MSS colorectal cancer, potentially targeting resistant tumors.
Mustang Bio’s MB-108, an HSV-1 oncolytic virus for malignant glioma, receives FDA Orphan Drug status, enhancing GBM treatment.
Kincell Bio appoints Stewart McNaull as CCO, enhancing its commitment to cell therapy innovation and client solutions.
CalciMedica appoints Stephen Bardin as CFO, bringing deep capital and finance expertise to advance company growth.
Aptar Pharma partners with CHI to launch Quattrii DPI, a platform aiming for efficient, high-dose respiratory drug delivery.
Geron raises $375M to advance RYTELO for blood cancers, supporting U.S. and EU launch, trials, and supply chain.
RNAi technology advances beyond liver treatments, with startups targeting CNS and genetic diseases using new delivery methods.
GC Cell partners with Artiva and Merck to advance two CAR-NK cancer therapies, assuming global R&D leadership rights.
Aurinia adds Craig Johnson to the Board of Directors, enhancing financial expertise as the company grows.
Collegium appoints Vikram Karnani as CEO. He brings leadership in rare disease pharmaceuticals and global expansion.
FDA reviews oral phenylephrine efficacy, proposing removal from OTC nasal decongestants. Public feedback is invited before a final decision. Learn more.
Grünenthal and Averitas Pharma complete enrollment for Phase III trial of QUTENZA® in post-surgical neuropathic pain, with results expected in 2025.
Biocon’s Bengaluru site receives FDA VAI status post-inspection, with minor issues not requiring regulatory action.
India’s ₹500 crore scheme aims to enhance local medical device manufacturing, reduce imports, and promote innovation.
Corvus presents promising data on ciforadenant's role in reducing immunotherapy resistance in metastatic prostate cancer.
GI Innovation's GI-101A and GI-108 show potential to enhance CAR-T therapy durability and counter tumour immunity challenges.
Merck strengthens its presence in Korea by investing in life sciences and semiconductors and forming a collaborative partnership with KAIST.
Swissport’s Madrid and Barcelona cargo centres receive GDP certification, boosting the global pharma logistics network.
Clarity teams with Nucleus RadioPharma to boost 67Cu-SAR-bisPSMA manufacturing and prepare for U.S. commercialization.
Recce Pharmaceuticals receives ethics approval to start a Phase 3 trial in Indonesia for R327G gel, targeting diabetic foot infections.
Boost immunity with Thymotas by Intas, featuring Thymoquinone. Clinically tested, it supports recovery, fights infections, and enhances overall immune health.
Indaptus’s Decoy20 platform combines innate and adaptive immune activation, showing promise for durable cancer therapy responses.
ARS Pharma licenses ALK exclusive rights to commercialise neffy, a needle-free epinephrine spray, in Europe, Canada, and geographies.
Pharma Two B and Hepion secure SEC approval for the merger, aiming to close in late 2024 pending shareholder vote.
RAPT Therapeutics halts the zelnecirnon program for asthma and dermatitis after the FDA holds the trials due to a severe liver injury case.
AbbVie’s Phase 2 EMPOWER trials for emraclidine in schizophrenia did not meet the efficacy target, while the safety profile was acceptable.
GenScript opens a logistics center in Sydney, improving delivery efficiency and supporting Australia’s biotech growth.
Longeveron appoints Devin Blass as CTO and Senior VP of CMC to lead technological and manufacturing strategies.
Citius Pharmaceuticals and Citius Oncology reveal promising Phase I trial results combining pembrolizumab with LYMPHIR™ for recurrent solid tumors.
Koneksa appoints Eric Luthi as Chief Business Officer, bringing 25+ years of life sciences expertise to lead business development and strategic partnerships.
Altimmune appoints Greg Weaver as CFO, bringing more than 25 years of experience in biotech finance and capital market expertise.
Syndax’s Phase 2 trial of revumenib for relapsed AML shows 23% remission and 47% response rate, with manageable side effects.
Spyre's SPY001, an α4β7-targeting antibody, shows promise for IBD with a 90+ day half-life, Phase 2 in 2025
Tempest Therapeutics advances to Phase 3 trial with FDA approval to test liver cancer drugs in combination therapy.
AstraZeneca and Daiichi Sankyo submit new BLA for EGFR-mutated lung cancer drug adjust trials based on FDA feedback.
Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO, succeeding Steven Ratoff, who remains on the board.
The KOMET trial demonstrates Koselugo's effectiveness for adult patients with inoperable plexiform neurofibromas in NF1.
Recursion's OpenPhenom-S/16 enhances microscopy data analysis in Vertex AI, aiding life sciences and drug discovery
Syros’ Phase 3 trial of tamibarotene with azacitidine fails to meet the primary endpoint for CR in HR-MDS patients, causing loan default.
Kane Biotech’s acquisition of FB Dermatology boosts wound care and skin treatment products in Europe, Australia, and the U.S.
AstraZeneca announces a $3.5B U.S. investment to expand R&D, manufacturing, and create 1,000+ jobs by 2026.
Longboard Pharmaceuticals launches Phase 3 trial of bexicaserin for seizures in Developmental and Epileptic Encephalopathies.
Rhythm’s setmelanotide trial shows BMI and hunger reduction in young children with genetic obesity syndromes, FDA review pending.
Tarsus Pharmaceuticals welcomes Dr. Kate Goodrich to its Board, bringing expertise in clinical leadership and health equity.
A new study shows diabetes cases have multiplied by four since 1990, with 800 million adults affected and treatment gaps in LMICs.
X4's study finds a daily mavorixafor safely raising ANC in chronic neutropenia, reducing G-CSF doses for many patients.
Zentalis Pharmaceuticals names Julie Eastland CEO and Scott Myers Board Chair as it advances azenosertib registrational studies.
Eli Lilly’s three-year study shows tirzepatide reduces type 2 diabetes risk, supports weight loss, and improves health markers.
Continuity Biosciences focuses on advanced cell reprogramming, immune modulation, and drug delivery to treat chronic diseases.
Pulmatrix and Cullgen merge to advance targeted therapies for cancer and more, with Cullgen to lead the combined company. Expected closure by March 2025.
TRexBio raises $84M in Series B to advance immune therapies, pushing innovative autoimmune treatments closer to clinical trials.
Affinia and Forge Biologics partner to manufacture gene therapies under cGMP, targeting heart and neuro diseases.
FDA grants approval for Kebilidi, a pioneering gene therapy to treat AADC deficiency, improving motor skills in young patients.
Corvus’s ITK inhibitor, soquelitinib, reduces fibrosis and lung damage in systemic sclerosis models, showing strong preclinical results.
Health Canada approves Kane Biotech's revyve™ Antimicrobial Wound Gel, granting immediate market access in Canada.
Merck enters an exclusive deal with LaNova for LM-299, with a $588M upfront payment and up to $2.7B in milestones.
Relmada Therapeutics initiates Phase 1 SAD trial to evaluate REL-P11 as a potential treatment for metabolic disease.
Omega Therapeutics updates include new leadership, strategic partnerships, and progress in clinical trials for innovative therapies.
Cellectar secures Ac-225 supply from NorthStar, driving CLR 121225 radiotherapy development for hard-to-treat cancers.
Cue Biopharma appoints Dr. Daniel Baker as interim CDO while Dr. Anish Suri transitions to a research advisor role.
FDA to review Dupixent® for chronic spontaneous urticaria, offering new hope for patients unresponsive to antihistamines.
Avantor's Bridgewater Innovation Center boosts biomanufacturing and accelerates life sciences therapies.
Amgen loses $12B in market value after hidden MariTide trial data reveals potential bone density concerns, rebounds later.
Boehringer Ingelheim adopts Veeva Vault CRM, enhancing agility and innovation across commercial operations.
Revuforj® gains FDA approval as the first menin inhibitor for leukemia with KMT2A translocation, launching November.
CHMP recommends KEYTRUDA for EU approval in MPM; KEYNOTE-483 shows improved survival with chemotherapy combination.
Dr Raymond Zheng joins Harbour BioMed as CBO, focusing on global partnerships and strategic product development.
PreveCeutical sells IP assets to BioGene in a USD $1.35M deal, including cash & shares, with plans to distribute shares to shareholders soon.
Neurophet names CTO Kim Dong-hyeon as Co-CEO, aiming to enhance R&D and global operations ahead of its planned IPO
Sanofi invests €40M in its Lyon site to boost antibody production, supporting transplant and type 1 diabetes treatments while advancing immunology.
Eyenovia’s CHAPERONE study misses the primary endpoint; the company considers mergers, asset sales, or other strategies.
Barinthus' HBV003 trial highlights VTP-300 and nivolumab's potential to deliver functional hepatitis B cures.
Arbutus' Phase 2a trial shows a 50% functional cure rate in HBV patients with low HBsAg, using imdusiran and Interferon.
China’s NMPA accepts Ascentage Pharma’s NDA for lisaftoclax, a novel Bcl-2 inhibitor for relapsed CLL/SLL treatment.
G20 leaders back WHO’s cervical cancer elimination campaign, highlighting global progress in vaccines, testing, and care equity.
Carisma unveils preclinical data on engineered macrophages, showing promise in tackling liver fibrosis and advanced MASH at AASLD 2024.
Tagrisso gains EU approval recommendation for EGFR-mutated NSCLC, with Phase III trials showing 84% reduced progression risk.
Alnylam's nucresiran achieves >90% TTR reduction with a single dose in Phase 1, showing promise for biannual/annual dosing in ATTR amyloidosis.
EC approves AbbVie's ELAHERE®, the first ADC targeting FRα, offering new hope for platinum-resistant ovarian cancer patients across Europe.
Island Pharmaceuticals' ISLA-101 trial hits a key milestone, exploring its potential as a treatment and preventative for dengue fever.
NeuroBo rebrands as MetaVia, advancing cardiometabolic drug pipeline with key trials in MASH and obesity set for 2024-2025.
Medicus Pharma appoints Dr. Faisal Mehmud as CMO. With 20+ years in clinical development, he’ll boost the company’s drug pipeline and strategic initiatives.
CPHI PMEC India 2024, Nov 26–28, Greater Noida, showcases global pharma trends, machinery, and tech innovations.
Medexus completes pCPA negotiations for Trecondyv®, aiming to secure public drug plan availability for Canadian patients.
Eli Lilly’s muvalaplin reduces Lp(a) by 85.8% in Phase 2, offering a promising oral option for heart disease.